New treatment for high oxalate levels and kidney stones
SLC26A3 (DRA) Inhibitors for Treatment of Hyperoxaluria and Nephrolithiasis
This study is looking at a new way to help people with hyperoxaluria, a condition that can cause kidney stones, by blocking a protein in the colon that makes the body absorb too much oxalate, so that more oxalate can be removed through stool instead of ending up in the urine.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10877183 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treat hyperoxaluria, a condition characterized by high levels of oxalate in the urine that can lead to kidney stones and chronic kidney disease. The study focuses on inhibiting a specific protein, SLC26A3, in the colon that facilitates the absorption of oxalate, thereby promoting its excretion through stool. By blocking this protein, the researchers aim to reduce the amount of oxalate that enters the urine, potentially alleviating the risk of kidney stone formation and protecting kidney function. The research utilizes both animal models and human data to explore the effectiveness of these inhibitors.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with hyperoxaluria, particularly those with a history of kidney stones or chronic kidney disease.
Not a fit: Patients who do not have elevated oxalate levels or related kidney conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients suffering from hyperoxaluria and related kidney issues.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting oxalate absorption, suggesting potential for success in this novel treatment strategy.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Cil, Onur — University of California, San Francisco
- Study coordinator: Cil, Onur
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.